Please use this identifier to cite or link to this item:
|Title:||Advances in the treatment of multiple myeloma: the role of thalidomide|
|Authors:||Ribas, Christian [UNIFESP]|
Colleoni, Gisele Wally Braga [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
|Publisher:||Taylor & Francis Ltd|
|Citation:||Leukemia & Lymphoma. Abingdon: Taylor & Francis Ltd, v. 44, n. 2, p. 291-298, 2003.|
|Abstract:||Multiple myeloma (MM) accounts for 1% of all malignancies and 10% of malignant hematological neoplasms. in spite of high-dose therapy with stem cell rescue, relapse and disease resistance are common events in the course of the disease. Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation. Here, we review the underlying concepts and current clinical data regarding Thal in the treatment of MM.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.